Hepatology International

Article	Citations
The safety profile of endoscopic variceal ligation in patients with esophageal varices	120
HBV in pregnancy: time to consider tenofovir alafenamide (TAF)	101
Metabolically healthy obese and MAFLD: does weight status alone matter?	90
Platelets in acute liver failure: an innocent bystander or instigator?	86
Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk	68
Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network	67
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD	65
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial	57
Defining the evaluation standards for the cholangiocytic component in cHCC-CCA: a pathology-based perspective	57
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression	49
Pure laparoscopic versus open left lateral hepatectomy in pediatric living donor liver transplantation: a review and meta-analysis	47
Commentary on “Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled t	46
Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study	45
Response to: “Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues”	44
Methodological reflections on vasoconstrictor use in refractory ascites: bridging trial rigor and real-world relevance	44
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease	43
Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis	41
p53 regulates glucose metabolic reprogramming in MASLD-related hepatocellular carcinoma via modulating mitochondrial pyruvate carriers	39
Antioxidant, selenium and risk of nonalcoholic fatty liver disease, more than causality	38
Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria	38
Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis	37
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study	35
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis	35
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy	35
Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India	34

Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma	34
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes	34
Antibiotic prophylaxis in upper gastrointestinal bleeding with Child-Pugh A cirrhosis: need for objective infection markers and broader studies	34
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis	32
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets	32
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection	32
Reply to: “developing real‑world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond”	31
Liver-derived extracellular vesicles from patients with hepatitis B virus-related acute-on-chronic liver failure impair hepatic regeneration by inhibiting on FGFR2 signaling via miR-218-5p	31
Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated?	31
Targeting immuno-metabolism and anti-viral immune responses in chronic hepatitis B	31
Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute-on-chronic liver failure	30
Drug–drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study	30
Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis	30
Metabolic dysfunction-associated steatotic liver disease increases the incidence of metachronous liver metastases from TNM stage 0–II colorectal cancer	30
Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis	30
Gut microbes associated with functional cure of chronic hepatitis B	29
Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures	29
Correction to: Targeting ferroptosis in hepatocellular carcinoma	29
The relationship between CXCR6+CD8+T cells and clinicopathological parameters in patients with primary biliary cholangitis	28
Role of splenic hepatic elastography ratio in differentiating non-cirrhotic portal fibrosis and chronic liver disease in children and adolescents	27
The dynamic patterns of metabolic-associated fatty liver disease and its severity and risk of cardiovascular disease	27
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan	27
Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain	27
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients	26
Prospects for treatment of esophageal varices considering the safety of endoscopic band ligation	26
Image-matching digital macro-slide—a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma	26
Metabolic dysfunction associated fatty liver disease in healthy weight individuals	25
Correction: The interplay between lymphatic system and portal hypertension: a comprehensive review	25
Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1–AXL signal relay in liver cancer cells	25
Methodological considerations in linking depression to metabolic dysfunction-associated steatotic liver disease: insights for future study design	25
Maternal and perinatal outcome in pregnancies complicated with portal hypertension: a systematic review and meta-analysis	25
Novel and simplified model for the precise identification of concurrent bacterial infections in patients aged 60 years and older with acute-on-chronic liver diseases: a nationwide, multicentre, prospe	25
APASL STC 2025, Istanbul	25
Fecal microbiota transplantation in alcoholic hepatitis: new treatment paradigm or a shot in the dark?	25
Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study	24
The impact of artificial liver support system on intestinal microbiota and serum bile acid profiles in patients with acute-on-chronic liver failure: a prospective cohort study	24
Correction: Liver transplantation for acute-on-chronic liver failure	24
Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis	24
Enhancing the understanding and management of metabolic dysfunction-associated steatotic liver disease in colorectal cancer patients: insights and future directions	23
Downregulated VISTA enhances Th17 differentiation and aggravates inflammation in patients with acute-on-chronic liver failure	23
MAFLD, patient-centred care, and APASL	23
The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma	23
Stage-specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma	23
Native liver survival with therapeutic plasma exchange in acutely decompensated hepatic Wilson Disease: revisiting the Dhawan index	23
ChIP-seq analysis found IL21R, a target gene of GTF2I–the susceptibility gene for primary biliary cholangitis in Chinese Han	22
Distinct course of portal hypertension in patients with cirrhosis with gastric variceal bleeding as their first decompensation: a propensity score-matched study	22
Correction to: Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma	22
Liver decompensation: the yard stick that measures indications and adverse effects of human albumin infusion	22
The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study	21
The association between visceral adipocyte hypertrophy and NAFLD in subjects with different degrees of adiposity	21

Sleep patterns, genetic susceptibility, and risk of cirrhosis among individuals with nonalcoholic fatty liver disease	21
Comment on: Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment	21
Diagnostic yield and novel candidate genes by next generation sequencing in 166 children with intrahepatic cholestasis	21
AARC score and urine NGAL predict terlipressin non-response and mortality in patients with acute-on-chronic liver failure	21
Low skeletal muscle mass is associated with more severe histological features of non-alcoholic fatty liver disease in male	21
Recombinant human serum albumin: a true therapeutic substitute or merely a serum level elevator?	21
Distinctly altered lipid components in hepatocellular carcinoma relate to impaired T cell-dependent antitumor immunity	20
Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis	20
Enhancing the prognostic value of inflammatory markers in hepatocellular carcinoma: a thoughtful discussion	20
Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study	19
Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals	19
Gender differences in non-alcoholic fatty liver disease in obese children and adolescents: a large cross-sectional study	19
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD	19
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients	18
Benefit of adjuvant radiotherapy for gallbladder cancer: a comparability-based meta-analysis	18
Liver fat and a perturbed metabolic milieu: a consilience of factors driving liver cancer development	18
A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma	18
Skeletal muscle alterations indicate poor prognosis in cirrhotic patients: a multicenter cohort study in China	18
Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: a randomized double blind placebo controlled trial	18
Comments on: CT-based intratumoral and peritumoral radiomics to predict the treatment response to hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 in high-risk hepatocellular carcinoma	17
Drug-induced liver injury from herbal and dietary supplements: a problem in the East and West alike	17
Modified and alternative Baveno VI criteria based on age for ruling out high-risk varices in patients with compensated cirrhosis	17
Correction to: Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells	16
Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle	16
The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis	16
Integrated genomic analyses of hepatocellular carcinoma	16
Stem cells therapies for liver diseases: for current practice and future goals	16
Genetic predisposition of metabolic dysfunction-associated steatotic liver disease: a population-based genome-wide association study	16
Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study	16
Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis	16
Diet-derived antioxidants and nonalcoholic fatty liver disease: a Mendelian randomization study	16
Reduction of natural killer cells is associated with poor outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure	16
Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis	16
Oxidative stress triggers hyperdynamic circulation via central neural activation in portal hypertensive rats	16
PIRO-CIC model can predict mortality and futility of care in critically ill cirrhosis patients in the intensive care unit	16
Commentary on “Predictive value of soluble PD-1 for HBsAg loss in HBeAg-negative chronic hepatitis B patients: a prospective study”	16
Explainable attention-enhanced heuristic paradigm for multi-view prognostic risk score development in hepatocellular carcinoma	16
Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease	16
CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway	16
PIVKA-II combined with alpha-fetoprotein for the diagnostic value of hepatic tumors in children: a multicenter, prospective observational study	16
Reconsiderations for the liver donation from a living donor: addressing hepatic steatosis with weight loss preconditioning	15
Hepatitis B virus-related intrahepatic cholangiocarcinoma originates from hepatocytes	15
Consensus on the secondary prevention of primary liver cancer	15
New progress towards elimination of mother-to-child transmission of hepatitis B virus in China	15
The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion	15
Diagnosis and management of pediatric acute liver failure: consensus recommendations of the Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN)	15
Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective	15
Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma	15
Gut-microbiome composition and function in progression of alcohol-associated liver disease: going beyond western experiences	14
Metabolic implications of tenofovir alafenamide in chronic hepatitis B: a commentary on cardiovascular and lipid risks	14
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort	14
Reply to Letter to the Editor “Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations”	14
Editorial: The safety profile of endoscopic variceal ligation in patients with esophageal varices. Authors’ reply	14
Predictive power of portal pressure gradient remeasured shortly after transjugular intrahepatic portosystemic shunt	14
miR-98-5p as a novel biomarker suppress liver fibrosis by targeting TGFβ receptor 1	14
Nomograms should be noted	14
Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations	14
Global burden of cirrhosis and liver cancer due to alcohol: the past, present, and the future	14
Refining meta-analyses in advanced biliary tract cancer	13
Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC)	13
Influence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial	13
Correction to: Infuence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial	13
Comments on: Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis	13
Carbohydrate-deficient transferrin is a sensitive marker of alcohol consumption in fatty liver disease	13
Low platelets: a new and simple prognostic marker for patients with hepatitis E virus-related acute liver failure	13
Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease	13
Reply to: The best predictive model for post-SVR HCC: can it be universal?	13
Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019	13
Clinical practice guidelines on hemochromatosis: Asian Pacific Association for the Study of the Liver	13
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment	13
Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease	13
Correction to: Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease	13
Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma	12
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?	12
How non-alcoholic fatty liver disease and cirrhosis affect the heart	12
Autophagy and extracellular vesicles in the liver endothelium: friends or foes?	12
Safety of right liver donation after improving steatosis through weight loss in living donors: a retrospective study	12
Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period	12
Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers	12
Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma	12

Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled trial	12
Developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond	12
Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection	12
Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes	12
Comparison of the prognostic models for mortality in idiosyncratic drug-induced liver injury	12
Response to Letter to Editor: “Systemic inflammation and prognosis in HCC: a closer look”	12
The upregulation of Annexin A2 by TLR4 pathway facilitates lipid accumulation and liver injury via blocking AMPK/mTOR-mediated autophagy flux during the development of non-alcoholic fatty liver diseas	12
Management of spontaneous portosystemic shunts at the time of liver transplantation: treatment or observation? Results of a systematic review	11
Regarding the role of post-transplant inflammatory cytokine signature on predicting tumor recurrence after liver transplantation for hepatocellular carcinoma	11
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024	11
Synthetic miR-26a mimics delivered by tumor exosomes repress hepatocellular carcinoma through downregulating lymphoid enhancer factor 1	11
Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA	11
Complications of congenital portosystemic shunts: liver tumors are affected by shunt severity, but pulmonary and neurocognitive associations are not	11
Comments on: Addition of midodrine to albumin reduces the incidence of complications of large-volume paracentesis: an RCT comparing midodrine, terlipressin, and albumins	11
Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B	11
Risk stratification for patients with primary biliary cholangitis: early versus advanced-stage or non-cirrhosis versus cirrhosis?	11
Management of acute variceal bleeding: updated APASL guidelines	11
Key considerations in portal vein thrombosis management	11
Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease	11
GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial	11
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study	11
Acute kidney injury stage 1a increases mortality of patients with cirrhosis: a prospective multicenter cohort study	11
AI in fatty liver diseases: insights from recent research trends	11
Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure	11
The causes of death in patients with nonalcoholic steatohepatitis following liver transplantation stratified using pre-liver transplant BMI	11
Impact of plasma exchange on bilirubin reduction and neurological impairment in infantile acute liver failure	11
Efficacy and safety of precision-guided transjugular extrahepatic portosystemic shunt (TEPS) in the management of cavernous transformation of the portal vein with portal hypertension: a case series	11
Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis	11
Presence of sarcopenia identifies a special group of lean NAFLD in middle-aged and older people	11
Midodrine plus propranolol: potential problems and controversies behind remarkable efficacy	11
Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma	11
Impact of myosteatosis on outcomes after liver transplantation: a systematic review and meta-analysis	11